We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.